nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Vincristine—peripheral nervous system neoplasm	0.186	0.345	CbGbCtD
Bosentan—ABCB11—Doxorubicin—peripheral nervous system neoplasm	0.116	0.216	CbGbCtD
Bosentan—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0716	0.133	CbGbCtD
Bosentan—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0448	0.083	CbGbCtD
Bosentan—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0416	0.0771	CbGbCtD
Bosentan—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0307	0.0568	CbGbCtD
Bosentan—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0191	0.0354	CbGbCtD
Bosentan—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0175	0.0325	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.012	0.0221	CbGbCtD
Bosentan—EDNRA—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.00635	0.107	CbGpPWpGaD
Bosentan—EDNRB—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.0058	0.0976	CbGpPWpGaD
Bosentan—EDNRA—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.00415	0.0699	CbGpPWpGaD
Bosentan—EDNRB—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.00247	0.0416	CbGpPWpGaD
Bosentan—ABCB11—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.0019	0.032	CbGpPWpGaD
Bosentan—EDNRA—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.00177	0.0297	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00157	0.0264	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00155	0.0261	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—peripheral nervous system neoplasm	0.00153	0.0257	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.0014	0.0236	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00112	0.0189	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00111	0.0187	CbGpPWpGaD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.00109	0.0184	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00104	0.0175	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.001	0.0169	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000791	0.0133	CbGpPWpGaD
Bosentan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000764	0.0129	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000759	0.0128	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000744	0.0125	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000705	0.0119	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000696	0.0117	CbGpPWpGaD
Bosentan—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000649	0.0109	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.00063	0.0106	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000566	0.00953	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000543	0.00914	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000505	0.00849	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000498	0.00838	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000467	0.00786	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000451	0.00759	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—HRAS—peripheral nervous system neoplasm	0.00045	0.00757	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000447	0.00753	CbGpPWpGaD
Bosentan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000418	0.00704	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000411	0.00692	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000406	0.00683	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—AKT1—peripheral nervous system neoplasm	0.000397	0.00669	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000389	0.00655	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000383	0.00645	CbGpPWpGaD
Bosentan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000382	0.00644	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000364	0.00613	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000356	0.00598	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000339	0.0057	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000334	0.00562	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—HRAS—peripheral nervous system neoplasm	0.000322	0.00542	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00032	0.00539	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000311	0.00523	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000308	0.00518	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000291	0.00489	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—AKT1—peripheral nervous system neoplasm	0.000284	0.00479	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000284	0.00478	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000279	0.00469	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000274	0.00462	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000271	0.00456	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000254	0.00428	CbGpPWpGaD
Bosentan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000252	0.00424	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000243	0.00408	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.00024	0.00404	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00024	0.00404	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.00023	0.00388	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00023	0.00387	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000222	0.00374	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00022	0.00371	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000203	0.00342	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000201	0.00338	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000183	0.00308	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000182	0.00307	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000182	0.00306	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000176	0.00296	CbGpPWpGaD
Bosentan—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000172	0.00043	CcSEcCtD
Bosentan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000172	0.000429	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000172	0.00289	CbGpPWpGaD
Bosentan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000172	0.000428	CcSEcCtD
Bosentan—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.000428	CcSEcCtD
Bosentan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000171	0.000428	CcSEcCtD
Bosentan—Hypotension—Etoposide—peripheral nervous system neoplasm	0.00017	0.000424	CcSEcCtD
Bosentan—Pain—Cisplatin—peripheral nervous system neoplasm	0.00017	0.000424	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000169	0.00284	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000168	0.00282	CbGpPWpGaD
Bosentan—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000418	CcSEcCtD
Bosentan—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000418	CcSEcCtD
Bosentan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000167	0.000417	CcSEcCtD
Bosentan—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000417	CcSEcCtD
Bosentan—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000416	CcSEcCtD
Bosentan—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000414	CcSEcCtD
Bosentan—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000414	CcSEcCtD
Bosentan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000413	CcSEcCtD
Bosentan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000165	0.000413	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000165	0.00278	CbGpPWpGaD
Bosentan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000165	0.000411	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000165	0.00277	CbGpPWpGaD
Bosentan—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.00041	CcSEcCtD
Bosentan—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000163	0.000408	CcSEcCtD
Bosentan—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000163	0.000407	CcSEcCtD
Bosentan—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000405	CcSEcCtD
Bosentan—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000162	0.000405	CcSEcCtD
Bosentan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000404	CcSEcCtD
Bosentan—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000162	0.000404	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000403	CcSEcCtD
Bosentan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000161	0.000402	CcSEcCtD
Bosentan—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000161	0.000401	CcSEcCtD
Bosentan—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000399	CcSEcCtD
Bosentan—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000399	CcSEcCtD
Bosentan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00016	0.000399	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.00016	0.00269	CbGpPWpGaD
Bosentan—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000398	CcSEcCtD
Bosentan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000159	0.000398	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000396	CcSEcCtD
Bosentan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000158	0.000395	CcSEcCtD
Bosentan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000158	0.000395	CcSEcCtD
Bosentan—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000392	CcSEcCtD
Bosentan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000157	0.000392	CcSEcCtD
Bosentan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000157	0.000392	CcSEcCtD
Bosentan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000157	0.000391	CcSEcCtD
Bosentan—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000389	CcSEcCtD
Bosentan—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000389	CcSEcCtD
Bosentan—Pain—Etoposide—peripheral nervous system neoplasm	0.000156	0.000388	CcSEcCtD
Bosentan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000156	0.000388	CcSEcCtD
Bosentan—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000388	CcSEcCtD
Bosentan—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000388	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000387	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000387	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000385	CcSEcCtD
Bosentan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000154	0.000385	CcSEcCtD
Bosentan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000154	0.000383	CcSEcCtD
Bosentan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000382	CcSEcCtD
Bosentan—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000152	0.00038	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000152	0.00256	CbGpPWpGaD
Bosentan—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000377	CcSEcCtD
Bosentan—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000377	CcSEcCtD
Bosentan—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000376	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000375	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000374	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000373	CcSEcCtD
Bosentan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000149	0.000373	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000371	CcSEcCtD
Bosentan—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000149	0.000371	CcSEcCtD
Bosentan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000148	0.000371	CcSEcCtD
Bosentan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000148	0.00037	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000369	CcSEcCtD
Bosentan—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000369	CcSEcCtD
Bosentan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000147	0.000367	CcSEcCtD
Bosentan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000147	0.000366	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000366	CcSEcCtD
Bosentan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000146	0.000365	CcSEcCtD
Bosentan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000365	CcSEcCtD
Bosentan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000146	0.000364	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000363	CcSEcCtD
Bosentan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000144	0.000361	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000144	0.00036	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.00036	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.00036	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000144	0.00242	CbGpPWpGaD
Bosentan—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000144	0.000359	CcSEcCtD
Bosentan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000144	0.000359	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000359	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000359	CcSEcCtD
Bosentan—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000358	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000358	CcSEcCtD
Bosentan—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000356	CcSEcCtD
Bosentan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000143	0.000356	CcSEcCtD
Bosentan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000142	0.000355	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000354	CcSEcCtD
Bosentan—Rash—Vincristine—peripheral nervous system neoplasm	0.000142	0.000353	CcSEcCtD
Bosentan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000141	0.000353	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000353	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000352	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000351	CcSEcCtD
Bosentan—Headache—Vincristine—peripheral nervous system neoplasm	0.000141	0.000351	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000349	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000348	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000346	CcSEcCtD
Bosentan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000138	0.000345	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000137	0.00231	CbGpPWpGaD
Bosentan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000136	0.000339	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000339	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000337	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000335	CcSEcCtD
Bosentan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000134	0.000334	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000334	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000333	CcSEcCtD
Bosentan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000133	0.000333	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000332	CcSEcCtD
Bosentan—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000332	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000331	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000331	CcSEcCtD
Bosentan—ABCB11—Metabolism—GNS—peripheral nervous system neoplasm	0.000132	0.00223	CbGpPWpGaD
Bosentan—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.00033	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000327	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000326	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000131	0.0022	CbGpPWpGaD
Bosentan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.00013	0.000326	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000325	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000325	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00013	0.00219	CbGpPWpGaD
Bosentan—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000323	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000323	CcSEcCtD
Bosentan—Chills—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000321	CcSEcCtD
Bosentan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000129	0.000321	CcSEcCtD
Bosentan—ABCB11—Metabolism—NME1—peripheral nervous system neoplasm	0.000127	0.00213	CbGpPWpGaD
Bosentan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000126	0.000315	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000126	0.00212	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000126	0.00212	CbGpPWpGaD
Bosentan—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000314	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000313	CcSEcCtD
Bosentan—Rash—Cisplatin—peripheral nervous system neoplasm	0.000125	0.000312	CcSEcCtD
Bosentan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000125	0.000312	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000312	CcSEcCtD
Bosentan—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000312	CcSEcCtD
Bosentan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000124	0.000311	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.00031	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000309	CcSEcCtD
Bosentan—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000308	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000308	CcSEcCtD
Bosentan—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000307	CcSEcCtD
Bosentan—ABCB11—Metabolism—COX2—peripheral nervous system neoplasm	0.000122	0.00205	CbGpPWpGaD
Bosentan—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000302	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000121	0.00203	CbGpPWpGaD
Bosentan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000301	CcSEcCtD
Bosentan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00012	0.0003	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.00012	0.0003	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00012	0.00202	CbGpPWpGaD
Bosentan—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000299	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000299	CcSEcCtD
Bosentan—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000297	CcSEcCtD
Bosentan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000118	0.000294	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000294	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.00029	CcSEcCtD
Bosentan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000116	0.000289	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000288	CcSEcCtD
Bosentan—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000288	CcSEcCtD
Bosentan—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000288	CcSEcCtD
Bosentan—Rash—Etoposide—peripheral nervous system neoplasm	0.000115	0.000286	CcSEcCtD
Bosentan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000115	0.000286	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000114	0.00192	CbGpPWpGaD
Bosentan—Headache—Etoposide—peripheral nervous system neoplasm	0.000114	0.000284	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000284	CcSEcCtD
Bosentan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000112	0.00028	CcSEcCtD
Bosentan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000112	0.00028	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000279	CcSEcCtD
Bosentan—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000279	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000277	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000111	0.00187	CbGpPWpGaD
Bosentan—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000275	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000274	CcSEcCtD
Bosentan—Cough—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000272	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000272	CcSEcCtD
Bosentan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000108	0.00027	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000108	0.00181	CbGpPWpGaD
Bosentan—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000267	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000265	CcSEcCtD
Bosentan—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000265	CcSEcCtD
Bosentan—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000264	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000264	CcSEcCtD
Bosentan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000262	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000104	0.00026	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000259	CcSEcCtD
Bosentan—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000259	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000258	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000103	0.00173	CbGpPWpGaD
Bosentan—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000255	CcSEcCtD
Bosentan—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000254	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000254	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000254	CcSEcCtD
Bosentan—Infection—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000253	CcSEcCtD
Bosentan—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000252	CcSEcCtD
Bosentan—Shock—Epirubicin—peripheral nervous system neoplasm	0.0001	0.00025	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.0001	0.00025	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	9.98e-05	0.000249	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	9.95e-05	0.000248	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	9.9e-05	0.000247	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	9.86e-05	0.000246	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	9.84e-05	0.000246	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	9.84e-05	0.000246	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	9.81e-05	0.000245	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	9.77e-05	0.000244	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	9.72e-05	0.000243	CcSEcCtD
Bosentan—Anorexia—Epirubicin—peripheral nervous system neoplasm	9.72e-05	0.000243	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	9.62e-05	0.00024	CcSEcCtD
Bosentan—Hypotension—Epirubicin—peripheral nervous system neoplasm	9.53e-05	0.000238	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	9.43e-05	0.000235	CcSEcCtD
Bosentan—Oedema—Doxorubicin—peripheral nervous system neoplasm	9.43e-05	0.000235	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.42e-05	0.00159	CbGpPWpGaD
Bosentan—Infection—Doxorubicin—peripheral nervous system neoplasm	9.37e-05	0.000234	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	9.29e-05	0.000232	CcSEcCtD
Bosentan—Shock—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	0.000232	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.000231	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	9.24e-05	0.00023	CcSEcCtD
Bosentan—Insomnia—Epirubicin—peripheral nervous system neoplasm	9.22e-05	0.00023	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	9.21e-05	0.00023	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	9.16e-05	0.000229	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	9.15e-05	0.000228	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	9.12e-05	0.000228	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	9.09e-05	0.000227	CcSEcCtD
Bosentan—Somnolence—Epirubicin—peripheral nervous system neoplasm	9.06e-05	0.000226	CcSEcCtD
Bosentan—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.04e-05	0.00152	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	9.02e-05	0.00152	CbGpPWpGaD
Bosentan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000224	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	8.97e-05	0.000224	CcSEcCtD
Bosentan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	8.86e-05	0.000221	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	8.81e-05	0.00022	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	8.8e-05	0.00022	CcSEcCtD
Bosentan—Fatigue—Epirubicin—peripheral nervous system neoplasm	8.79e-05	0.000219	CcSEcCtD
Bosentan—Pain—Epirubicin—peripheral nervous system neoplasm	8.72e-05	0.000218	CcSEcCtD
Bosentan—Constipation—Epirubicin—peripheral nervous system neoplasm	8.72e-05	0.000218	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	8.59e-05	0.000214	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000213	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	8.47e-05	0.000211	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	8.41e-05	0.00021	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	8.39e-05	0.000209	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	8.34e-05	0.000208	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	8.3e-05	0.000207	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	8.2e-05	0.000205	CcSEcCtD
Bosentan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.14e-05	0.000203	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	8.13e-05	0.000203	CcSEcCtD
Bosentan—Urticaria—Epirubicin—peripheral nervous system neoplasm	8.1e-05	0.000202	CcSEcCtD
Bosentan—Pain—Doxorubicin—peripheral nervous system neoplasm	8.07e-05	0.000201	CcSEcCtD
Bosentan—Constipation—Doxorubicin—peripheral nervous system neoplasm	8.07e-05	0.000201	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	8.06e-05	0.000201	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	8.06e-05	0.000201	CcSEcCtD
Bosentan—ABCB11—Metabolism—ENO2—peripheral nervous system neoplasm	8.01e-05	0.00135	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.93e-05	0.00134	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	7.71e-05	0.000193	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.71e-05	0.0013	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.000187	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	7.49e-05	0.000187	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.000186	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.000186	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.35e-05	0.00124	CbGpPWpGaD
Bosentan—Asthenia—Epirubicin—peripheral nervous system neoplasm	7.31e-05	0.000183	CcSEcCtD
Bosentan—Pruritus—Epirubicin—peripheral nervous system neoplasm	7.21e-05	0.00018	CcSEcCtD
Bosentan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6.98e-05	0.000174	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.000173	CcSEcCtD
Bosentan—ABCB11—Metabolism—BCHE—peripheral nervous system neoplasm	6.77e-05	0.00114	CbGpPWpGaD
Bosentan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	6.77e-05	0.000169	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.74e-05	0.00114	CbGpPWpGaD
Bosentan—Dizziness—Epirubicin—peripheral nervous system neoplasm	6.74e-05	0.000168	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	6.67e-05	0.000167	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.67e-05	0.00112	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.55e-05	0.0011	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000162	CcSEcCtD
Bosentan—ABCB11—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.46e-05	0.00109	CbGpPWpGaD
Bosentan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	6.45e-05	0.000161	CcSEcCtD
Bosentan—Rash—Epirubicin—peripheral nervous system neoplasm	6.43e-05	0.00016	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	6.42e-05	0.00016	CcSEcCtD
Bosentan—Headache—Epirubicin—peripheral nervous system neoplasm	6.39e-05	0.000159	CcSEcCtD
Bosentan—ABCB11—Metabolism—TH—peripheral nervous system neoplasm	6.37e-05	0.00107	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.24e-05	0.000156	CcSEcCtD
Bosentan—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.11e-05	0.00103	CbGpPWpGaD
Bosentan—Nausea—Epirubicin—peripheral nervous system neoplasm	6.06e-05	0.000151	CcSEcCtD
Bosentan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	6e-05	0.00015	CcSEcCtD
Bosentan—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.96e-05	0.001	CbGpPWpGaD
Bosentan—Rash—Doxorubicin—peripheral nervous system neoplasm	5.95e-05	0.000148	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	5.94e-05	0.000148	CcSEcCtD
Bosentan—Headache—Doxorubicin—peripheral nervous system neoplasm	5.91e-05	0.000147	CcSEcCtD
Bosentan—Nausea—Doxorubicin—peripheral nervous system neoplasm	5.6e-05	0.00014	CcSEcCtD
Bosentan—ABCB11—Metabolism—GNAS—peripheral nervous system neoplasm	5.2e-05	0.000875	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.18e-05	0.000871	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ABCB1—peripheral nervous system neoplasm	5.1e-05	0.000859	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.08e-05	0.000855	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.88e-05	0.000821	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.77e-05	0.000803	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.74e-05	0.000798	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.7e-05	0.000791	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.69e-05	0.000789	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	4.42e-05	0.000743	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.31e-05	0.000725	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	4.23e-05	0.000713	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	4.08e-05	0.000686	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.03e-05	0.000678	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.94e-05	0.000663	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.7e-05	0.000624	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.67e-05	0.000617	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.49e-05	0.000588	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.39e-05	0.000571	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.36e-05	0.000566	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.08e-05	0.000519	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.01e-05	0.000507	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.91e-05	0.00049	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.88e-05	0.000485	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.82e-05	0.000474	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.79e-05	0.00047	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.69e-05	0.000452	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	2.68e-05	0.00045	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.63e-05	0.000442	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.54e-05	0.000428	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	2.26e-05	0.000381	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.16e-05	0.000363	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.16e-05	0.000363	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	2.13e-05	0.000358	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.06e-05	0.000347	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000306	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.76e-05	0.000297	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.74e-05	0.000292	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.7e-05	0.000287	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.49e-05	0.000251	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.42e-05	0.000239	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—peripheral nervous system neoplasm	1.4e-05	0.000236	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.4e-05	0.000236	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.14e-05	0.000193	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.12e-05	0.000189	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	4.68e-06	7.88e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.09e-06	5.2e-05	CbGpPWpGaD
